Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human B-cell receptors (BCRs) and the resulting neutralizing antibodies specific for the Human Papillomavirus (HPV) L1 major capsid protein are critical components of the adaptive immune response against HPV infection (Source: PubMed, PMID: 28935464). These receptors specifically recognize complex, three-dimensional conformational epitopes presented on the surface of L1 virus-like particles (VLPs), which mimic the structure of the actual virus (Source: NIH, National Cancer Institute). Upon binding, BCRs trigger the maturation of B-cells into plasma cells that secrete high-affinity neutralizing antibodies (Source: UniProt, P03101). These antibodies provide prophylactic protection by binding to the L1 protein of the virus, effectively blocking its ability to interact with host cell receptors and enter the basal epithelium (Source: CDC, HPV Vaccine Information). This mechanism is the primary basis for the high efficacy of current HPV vaccines, such as Gardasil 9, which are designed to elicit a robust and long-lasting antibody response to prevent HPV-related malignancies (Source: FDA, Gardasil 9 Label). The specificity of these antibodies for conformational epitopes ensures that they only target intact, infectious virions or VLPs, making them highly precise tools of the immune system (Source: PubMed, PMID: 11080583).
The B-cell receptors recognize conformational epitopes on the HPV L1 virus-like particles (VLPs), leading to B-cell activation, clonal expansion, and the production of high-affinity neutralizing antibodies. These antibodies bind to the L1 protein on the surface of the HPV virion, sterically hindering the virus from attaching to and entering host basal epithelial cells, thereby preventing infection (Source: PubMed, PMID: 28935464).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human B-cell receptor specific for Human Papillomavirus L1 major capsid protein (HPV L1-specific BCR).